Research programme: chimeric antigen receptor macrophages therapeutics - Carisma Therapeutics
Latest Information Update: 24 Jul 2024
At a glance
- Originator Carisma Therapeutics
- Class Cell therapies; Gene therapies
- Mechanism of Action Macrophage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hepatic fibrosis; Pulmonary fibrosis
- Research Autoimmune disorders; Neurological disorders